The FDA is shifting away from animal testing in the development of monoclonal antibody therapies and other drugs.

The FDA is moving away from requiring animal models for investigational new drug (IND) applications for new monoclonal ...

This is a groundbreaking step toward advancing public health by using more effective and human-relevant methods instead of ...

The FDA laid out a three-year roadmap to phase out animal toxicity testing in drug research. In addition to organoids and lab ...

Since 1938, animal testing has been required by the FDA before any new drug can proceed through clinical trials and receive ...

The FDA will begin replacing animal testing in the development of monoclonal antibody therapies and other drugs with ...

The U.S. Food and Drug Administration is replacing animal testing with human-relevant methods, including artificial ...

Analysts at William Blair expect drug developers will continue to perform “at least some animal testing” on their ...

In laboratory tests of the antibody painting platform on mouse and human IgGs, the researchers found that nearly half of all antibodies successfully attached to GLP-1 receptor agonists at a body ...

The team created a novel tick antigen library housing over 3,000 different proteins, testing each to create a target cocktail ...

The US Food and Drug Administration announced Thursday that it will be phasing out a requirement that monoclonal antibodies ...

The initiative, which will start with monoclonal antibodies, is the first big regulatory shift from the FDA since Martin ...